Teva failed to show that it would suffer "irreparable harm" if the stay was not issued. The Court could announce its decision at any time. A ruling on the case might not happen until mid-2015. ( NVS ) ( MYL ) ( MNTA ) Post your comment!
accepted the case on March 31 but will not hear oral arguments until October and a ruling might not happen until mid-2015. Teva believes it will suffer "irreparable harm" if other generics are allowed to market. ( MNTA ) Post your comment!
PACB +13% . INSM +13% . BLDR +13% . CWEI +12% . ASTM +12% . OMED +12% . Top 10 Losers: WHX -27% . MNKD -15% . MNTA -15% . GPRC -15% . FATE -13% . OTC:PFIE -13% . OTCPK:MRNA -12% . UTIW -9% . SORL -9% . OBCI -8% . Post your
Shares of generic drug maker Momenta Pharmaceuticals ( MNTA -11.4% ) are down in early trading after the Supreme Court agrees to hear Teva's ( TEVA +4.7% ) appeal of a lower court
Likewise, the news is a slight negative for two of the major contenders attempting a generic Copaxone: Momenta Pharmaceuticals and Mylan. Negative shifts in our fair value estimates for both of these companies from potential generic
Increasing pharmaceutical complexity shines light on Momenta's capabilities.
We’re leaving our fair value estimate for Momenta Pharmaceuticals unchanged after the company reported third-quarter results within our expectations. Momenta reported a net loss of $25.4 million
We're raising our fair value estimate for Momenta Pharmaceuticals to $16 per share after updating our forecast for a potential generic Copaxone launch to 2014 from 2015 following the recent U
decision is a positive for the two major contenders attempting to manufacture generic versions of Copaxone, Mylan MYL and Momenta MNTA . We may slightly increase our fair value estimates for both of these firms as we reevaluate our assumptions. We plan to adjust
Momenta Pharmaceutical's MNTA first-quarter results mostly met our expectations, but volatility from market share shifts and pricing pressure in the generic